Holly Martinson,1 Jun Qin,2 David M. Virshup,3 and Anjana Rao1*
CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115,1 Verna and Mars McLean Department of Biochemistry and Molecular Biology and the Department of Cellular and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030,2 Department of Oncological Sciences, Huntsman Cancer Institute, and Department of Pediatrics, University of Utah, Salt Lake City, Utah 841123
Received 2 December 2003/ Returned for modification 5 January 2004/ Accepted 17 February 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
B, NFAT, and Pho4 signaling pathways (reviewed in references 7, 27, and 31). In each of these cases, phosphorylation is utilized as a means of regulating nuclear translocation of the latent cytoplasmic transcription factor, although the precise mechanisms and signaling pathways involved differ widely. NFAT is an example of a latent transcription factor whose subcellular localization, DNA binding, and transcriptional activity are all dictated by its phosphorylation state. The NFAT family is composed of four calcium-regulated members, NFAT1 (also known as NFATc2 or NFATp), NFAT2 (NFATc1, NFATc), NFAT3 (NFATc4), and NFAT4 (NFATc3, NFATx), that play an essential role in immune function as well as in development of the cardiac, vascular, and immune systems (reviewed in references 12 and 18). NFAT proteins are located in the cytoplasm of resting cells, where they exist in a heavily phosphorylated inactive state. In response to calcium-mobilizing stimuli they are partially dephosphorylated by calcineurin, a calcium-dependent phosphatase, and translocate into the nucleus (reviewed in references 11, 23, 29, and 45). Treatment of stimulated cells with calcium chelators or the calcineurin inhibitor cyclosporin A (CsA) results in the rapid rephosphorylation of NFAT and its export out of the nucleus.
The responsiveness of NFAT proteins to calcium signaling is mediated through their regulatory domains, which contain both the calcineurin binding site and the majority of the serine residues that are phosphorylated in resting cells. Mass spectrometric analysis has demonstrated that the regulatory domain of NFAT1 is constitutively phosphorylated at 18 serine residues in resting T cells (41). Twelve of these phosphorylated residues are contained within two distinct types of serine-rich sequence motifs, the SRR-1 and SPXX repeat motifs (referred to below as SP motifs), which are recognizably conserved throughout the NFAT family (see Fig. 1A). The SRR-1 region is the primary region involved in NFAT nuclear import, whereas the SP motifs have been reported to control DNA-binding affinity and nuclear export (5, 40, 41). Several kinases, including glycogen synthase kinase 3 (GSK3), casein kinase 1 (CK1), p38, and c-Jun N-terminal kinase 1 (JNK1), have been suggested to regulate NFAT function (6, 10, 17, 42, 56, 58; reviewed in references 23 and 29). However, no single proposed kinase displays the specificity required for full phosphorylation of both the SRR-1 and SP motifs.
|
| MATERIALS AND METHODS |
|---|
|
|
|---|
, pV371, encoding full-length CK1
with an HA tag, and pV570, encoding HA-tagged CK1
truncated at amino acid 319, have been described elsewhere (46). The NFAT1 fusion constructs GST-NFAT1(149-183) and GST-NFAT1(1-100) were created by subcloning PCR products generated from murine NFAT1 into pGEX6P-2. The NFAT1(LDFS), NFAT1(DE), NFAT1(F30F34), and NFAT1(F34) point mutations were created by synthesizing oligonucleotides containing the appropriate substitutions, which were then used as PCR primers. The resulting PCR products were used to replace the corresponding sequences encoded in the GST-NFAT1(1-100) and NFAT1(1-460)-GFP (4) expression vectors.
Protein purification and kinase assays.
Whole-cell extracts were prepared by Dounce homogenization of Jurkat cells in hypotonic lysis buffer (50 mM Tris [pH 7.9], 10 mM NaCl, 10% glycerol, 0.05% Triton X-100, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol [DTT], 20 mM ß-glycerol-phosphate, 10 mM sodium pyrophosphate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride [PMSF], 10 µg of aprotinin/ml, 10 µg of leupeptin/ml). Lysates were spun for 10 min at 20,000 x g, followed by a high-speed spin for 1 h at 100,000 x g in the ultracentrifuge. The supernatant was loaded onto a POROS HQ column (Applied Biosystems) and eluted with a 0 to 400 mM NaCl gradient. In vitro kinase assays were performed on GST-NFAT1 fusion proteins by incubating column fractions and kinase buffer (20 mM HEPES, 20 mM MgCl2, 1 mM DTT, 10 mM ß-glycerol-phosphate) in a final volume of 30 µl in the presence of 20 µM ATP and 2 µCi of [
-32P]ATP for 20 min at 30°C. Fractions enriched for NFAT1 kinase activity were pooled and dialyzed against buffer B (50 mM HEPES [pH 7.2], 10% glycerol, 1 mM DTT, 1 mM PMSF) before fractionation over a POROS HS column (Applied Biosystems). Proteins were eluted by using a NaCl step gradient, and the bulk of SRR-1 kinase activity was observed between 400 and 500 mM NaCl. After concentration on a Centriplus 30 spin column (Amersham), the sample was loaded onto a Superdex 200 gel filtration column (Pharmacia). Fractions were analyzed for NFAT1 SRR-1 kinase activity and were subjected to silver staining to identify candidate bands that coincided with the fractionation of this activity. Six bands that cofractionated with SRR-1 kinase activity were excised and analyzed by mass spectrometry. A prominent band between 35 and 40 kDa whose fractionation coincided most closely with kinase activity was identified as CK1
. Two other candidate bands of slightly lower molecular weight (presumably degradation products) also contained multiple peptides corresponding to CK1. No other kinases were identified in the mass spectrometry analysis.
The ability of GSK3 or CK1 to phosphorylate NFAT1 was examined by first prephosphorylating GST-NFAT fusion proteins with 100 U of recombinant protein kinase A (PKA) (New England Biolabs [NEB]) in the presence of 1 mM cold ATP for 4 h at 30°C. After being primed with PKA, fusion proteins were washed repeatedly to remove the kinase and ATP. The prephosphorylated fusion proteins were then incubated with 100 U of GSK3 (NEB) or 50 U of CK1 (NEB) in kinase buffer along with 3 µCi of [
-32P]ATP for 20 min at 30°C.
Coprecipitation and Western blotting.
Jurkat T cells were used for immunoprecipitation of endogenous NFAT1 and CK1. Either resting cells or cells that had been stimulated for 15 min with 1 µM ionomycin in the presence of 2 mM CaCl2 were lysed by resuspension in Triton X-100 lysis buffer (50 mM Tris [pH 7.5], 140 mM NaCl, 10% glycerol, 0.05% Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM ß-glycerol-phosphate, 1 mM PMSF, 10 µg of aprotinin/ml, 10 µg of leupeptin/ml). Lysates were spun for 10 min at 14,000 rpm in an Eppendorf 5417R microcentrifuge before spinning for 30 min at 100,000 x g in an ultracentrifuge. Supernatants were then precleared for 30 min with protein A-Sepharose before immunoprecipitation for 3 h with an NFAT1 antibody. For GST pulldown experiments, HEK 293 cells were transiently transfected with expression vectors containing CK1
(pV367) or CK1
(pV371). Cells were lysed in a buffer containing Triton X-100, and lysates were clarified by spinning at 20,000 x g for 15 min at 4°C. Cell lysates were incubated with GST or a GST-NFAT fusion protein bound to glutathione beads for 2 h at 4°C. Fusion proteins were washed with Triton X-100 lysis buffer, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and Western blotted with antibodies against CK1
(Santa Cruz Biotechnology) and CK1
(Transduction Laboratories) to detect bound proteins.
Immunocytochemistry.
For the nuclear export studies, the murine T-cell clone D5 (44) was incubated with 150 to 300 µM CKI-7 inhibitor (Seikagaku) and/or 10 mM LiCl (or an equivalent amount of dimethyl sulfoxide [DMSO] and 10 mM NaCl) for 1 h before being stimulated with 1 µM ionomycin in the presence of 2 mM CaCl2. After 10 min, 1 µM CsA was added to inhibit calcineurin activity and allow the rephosphorylation of NFAT1. Aliquots of cells were taken at the indicated intervals and fixed on coverslips, and localization of the endogenous NFAT1 was detected with a polyclonal anti-NFAT1 antibody (22) followed by Cy3-conjugated anti-rabbit immunoglobulin G (Jackson Immunoresearch Laboratories). For experiments examining the effect of CKI-7 or LiCl on resting NFAT1, we utilized a HeLa cell line stably expressing the regulatory domain of NFAT1 fused to green fluorescent protein (GFP) [NFAT(1-460)-GFP] (4). Cells were incubated for 2 h with the export inhibitor leptomycin B (LMB; Sigma) at 20 nM in addition to either DMSO, 10 mM LiCl, or 300 µM CKI-7. NFAT1 was detected by GFP fluorescence. To examine the effects of CKI-7 on CK1 and GSK3 activities, GST(1-415) was first primed with PKA as described above and then added to purified GSK3 (NEB) or CK1 (NEB) that had been preincubated with increasing concentrations of CKI-7 or 10 mM LiCl, along with [
-32P]ATP.
| RESULTS |
|---|
|
|
|---|
To identify the SRR-1 kinase, we fractionated whole-cell lysates from Jurkat cells over a series of ion-exchange and chromatography columns (see Materials and Methods). Fractions containing the largest amounts of SRR-1 kinase activity were pooled and loaded onto a gel filtration column (Fig. 2A). Silver-stained SDS-PAGE gels of the eluted fractions consistently showed two to three bands between 35 and 40 kDa that correlated strongly with the peak of SRR-1 kinase activity (Fig. 2A, fractions 87 to 90). Mass spectrometry demonstrated that these bands contained CK1
(see Materials and Methods). Western blot analysis of gel filtration fractions confirmed that peak SRR-1 kinase activity coincided precisely with the fractions containing the highest levels of CK1
(Fig. 2B, fractions 61 to 66). These fractions did not contain GSK3, which has been suggested to be the main regulatory kinase for two NFAT family members, NFAT2 and NFAT3 (6, 19) (see below).
|
, CK1
, and CK1
(reviewed in reference 21). Unlike CK1
, which has a very short C terminus, CK1
and CK1
possess a longer C-terminal region that becomes autophosphorylated in the presence of ATP, resulting in the rapid downregulation of kinase activity (8, 20, 46). Consequently, CK1
and CK1
are inefficiently detected by in vitro kinase assays (8), leading us to ask whether these kinases may have been overlooked during the multistep chromatography protocol used to purify CK1
as an NFAT kinase. Western blot analysis of fractions from each of the chromatography columns revealed that CK1
and CK1
cofractionated with CK1
and SRR-1 kinase activity through all but the final gel filtration step (Fig. 2C and data not shown), while GSK3 fractionated away from SRR-1 kinase activity at the very first chromatography step (Fig. 2C). These results strongly implicate CK1 proteins as SRR-1 kinases for NFAT1.
We tested whether GSK3 could also serve as an SRR-1 kinase for NFAT1 (Fig. 2D). Purified recombinant GSK3 was able to phosphorylate a fusion protein that encompassed the entire regulatory domain of NFAT1, but only if the substrate was previously phosphorylated in a "priming" step by PKA (Fig. 2D; compare lanes 1 and 2), similar to what has been reported for NFAT2 (6). Under identical conditions, GSK3 was also able to phosphorylate a shorter fusion protein containing the isolated NFAT1 SP-2 motif (Fig. 2D, lanes 3 and 4). However, GSK3 was incapable of phosphorylating the fragment that contained only the NFAT1 SRR-1 region, even after preincubation with PKA (Fig. 2D, lanes 5 and 6). In contrast, a recombinant CK1
kinase (lacking its autoinhibitory domain) phosphorylated the SRR-1 region robustly (lane 8). Similarly, a truncated version of CK1
lacking its autoinhibitory region also had strong SRR-1 kinase activity (data not shown). Taken together, these results demonstrate that CK1 is an NFAT1 SRR-1 kinase, while GSK3 phosphorylates residues in the NFAT1 SP-2 motif in conjunction with a priming kinase.
A high-molecular-weight complex containing NFAT1 and CK1.
Since enzymes in a signal transduction pathway often bind to their substrates, we asked whether CK1 proteins associated with NFAT (Fig. 3). We generated GST fusion proteins encompassing the N-terminal regulatory domains of NFAT family members NFAT1, NFAT2, and NFAT4. Stable interactions were readily detectable between the GST-NFAT fusion proteins and CK1
, CK1
(Fig. 3A), and CK1
(data not shown) from HEK 293 lysates. No interaction was detected between any CK1 kinase and GST alone (Fig. 3A). The interactions of CK1
and CK1
with NFAT1 and NFAT3 were also established by coimmunoprecipitating full-length proteins expressed in HEK 293 cells (Fig. 3B and data not shown) as well as endogenous proteins present in Jurkat T cells (Fig. 3C). The interaction mapped to the first 319 amino acids of CK1
(Fig. 3B, last lane), which contain its kinase domain; this domain is virtually identical to the kinase domain of CK1
and is closely related to that of CK1
(21). On NFAT1, the region of interaction mapped to the beginning of the N terminus, which contains its transactivation domain (amino acids 1 to 98) (Fig. 3D). These results show that there are stable interactions between CK1 kinases and each NFAT family member.
|
and CK1
kinases coeluted with NFAT1 (Fig. 4A, second panel; also data not shown). CK1
, which has a molecular mass of about 37 kDa, migrated through the column with two distinct peaks of elution: a fraction that eluted at the expected molecular weight for a CK1
monomer (fractions 88 to 90) and a second, high-molecular-weight fraction that coeluted with NFAT1 at an apparent molecular mass of
350 kDa (fractions 62 to 64). CK1
also demonstrated altered mobility on the size exclusion column, eluting mainly in two peaks: one that coincided with NFAT1 elution and a second at its expected molecular mass (
47 kDa) (data not shown). This is consistent with our findings that endogenous CK1
and CK1
can be coimmunoprecipitated with NFAT1 in T cells (Fig. 3C and 4C). In contrast, both isoforms of GSK3 eluted at their expected molecular masses, well separated from the fractions containing NFAT1 and CK1 (Fig. 4A, third panel). Calcineurin, the NFAT phosphatase, eluted at a molecular mass higher than that expected for the holoenzyme containing the catalytic A subunit and the regulatory B subunit but did not cofractionate with the NFAT1 high-molecular-weight complex.
|
and CK1
(Fig. 4 and data not shown). In contrast, there was only a minor change in the elution profile of NFAT1, suggesting the presence of other proteins in the NFAT1 complex. The elution profiles of GSK3 and calcineurin showed no change (Fig. 4B and data not shown). These results mirror those from immunoprecipitation experiments showing that NFAT1 from Jurkat cells associates with endogenous CK1
but that this interaction is almost undetectable in cells that have been stimulated with ionomycin (Fig. 4C). Thus, cell stimulation concomitantly activates the calcineurin phosphatase and leads to dissociation of the SRR-1 kinase. CK1 and GSK3 synergize to effect NFAT1 rephosphorylation and nuclear export. Termination of calcium and/or calcineurin signaling results in rephosphorylation of NFAT1 and its export from the nucleus. We used untransformed T cells in which we could monitor the behavior of endogenous NFAT1 to investigate whether CK1 or GSK3 plays a role in this process (Fig. 5). Since several different CK1 family members are able to bind and phosphorylate NFAT1 in vitro, we used CKI-7, a cell-permeant inhibitor that affects all known family members of CK1 (9). LiCl was used to inhibit GSK3 (30). To minimize nonspecific effects, we exposed cells to the inhibitors for 2 h or less.
|
Consistent with the delay in nuclear export, Western blotting demonstrated that the combination of CK1 and GSK3 kinase inhibitors resulted in a significant delay in the rephosphorylation of NFAT1 in T cells after CsA addition (Fig. 5B). The finding that the inhibitors delay NFAT1 rephosphorylation and nuclear export rather than blocking it completely most likely reflects the fact that even when tested in vitro, high concentrations of the inhibitors do not completely abolish the ability of recombinant CK1 or GSK3 to phosphorylate NFAT1 (Fig. 5C and D). Approximately 10 to 20% of kinase activity remains in vitro, and this amount of kinase activity is likely sufficient for slow rephosphorylation of NFAT1 in vivo. To ensure that CKI-7 and LiCl were acting specifically on CK1 and GSK3, respectively, we asked whether CKI-7 inhibited the kinase activity of purified GSK3 (Fig. 5C). Using GST(1-415) that had been prephosphorylated by PKA as a substrate, we showed that concentrations of CKI-7 that efficiently inhibited CK1 kinase activity did not alter the ability of GSK3 to phosphorylate the NFAT1 regulatory domain (Fig. 5C and D). Conversely, LiCl impaired GSK3 kinase activity by >70%, as expected, but had only a minor effect on CK1 kinase activity (Fig. 5C).
CK1 controls NFAT1 nuclear import. The greater effectiveness of CKI-7 than LiCl in prolonging the nuclear residence of NFAT1 (Fig. 5A) is consistent with the proposed role for CK1 in phosphorylating the SRR-1 motif, the primary region controlling nuclear localization signal exposure. It has been shown previously that phosphorylation of conserved serines within the SRR-1 region is critical for establishing and maintaining the cytoplasmic localization of NFAT1 (41). Serine-to-alanine mutation of conserved serines within the SRR-1 motif is sufficient to cause partial constitutive nuclear localization of NFAT1 in resting cells, even when the SP motifs remain fully phosphorylated. In contrast, mutation of the SP motifs alone has no effect on NFAT1 localization in resting cells (41). If CK1 is the major constitutive kinase for the NFAT1 SRR-1 region, inhibition of CK1 activity or disruption of CK1-NFAT1 association would be expected to gradually decrease phosphorylation of the SRR-1 region and promote partial nuclear localization of NFAT1 in resting cells, whereas inhibition of GSK3 or other SP motif kinases should have little or no effect.
HeLa cells stably expressing a GFP-NFAT1 fusion protein (Fig. 5E) were incubated with CKI-7 or LiCl in the presence of LMB (54), an inhibitor of NFAT nuclear export which facilitates detection of nuclear translocation by preventing any nucleocytoplasmic shuttling of NFAT (28, 41, 57). In control HeLa cells treated for 2 h with LMB but no kinase inhibitors, the bulk of NFAT1 is excluded from the nucleus (Fig. 5E, left panel). Cells treated with LMB and LiCl did not differ detectably from control cells (center panel); in contrast, cells treated with LMB and CKI-7 showed a noticeable increase in nuclear NFAT1 staining relative to that in cells treated with LMB alone, with similar intensities of NFAT1 staining in the nucleus and the cytoplasm (right panel). Identical results were observed for endogenous NFAT1 in T cells (data not shown). These results are completely consistent with our findings that CK1 is responsible for SRR-1 phosphorylation and that this region is, in turn, primarily responsible for NFAT1 nuclear import. Similarly, the fact that the GSK3 inhibitor LiCl did not promote the nuclear import of NFAT1 is consistent with our findings that GSK3 is an SP motif kinase but not an SRR-1 kinase and that mutations which mimic dephosphorylation of the SP motifs do not alter the subcellular distribution of NFAT1 in resting cells.
Mutation of the CK1 docking site deregulates NFAT1 localization. Although use of the CKI-7 inhibitor altered NFAT1 localization in cells, general concerns about inhibitor specificity led us to seek an additional method to validate the role of CK1 in NFAT1 regulation. Since NFAT1 and CK1 are stably associated in resting cells (Fig. 4), we asked whether disruption of the NFAT1-CK1 association would affect NFAT1 localization. We had mapped CK1 binding to the first 98 amino acids of NFAT1 (Fig. 3D). To identify potential docking motifs present in this region, we aligned the N-terminal sequences of the four NFAT proteins with the PER circadian-rhythm proteins (see Fig. 7A), which have also been shown to associate directly with CK1. Remarkably, this comparison identified a common F-X-X-X-F sequence, present both in the N-terminal region of NFAT proteins and in the region of PER proteins shown to bind CK1 (51, 53) (Fig. 7A). The CK1-binding region of NFAT1 also contains an LDFS motif (Fig. 7A), previously identified in a subset of helix-loop-helix transcription factors (38); however, this motif is only loosely conserved among members of the NFAT family and does not appear to be conserved in other CK1 targets.
|
|
target to bind to its regulatory kinase (Fig. 7B). Thus, the F-X-X-X-F motif may prove to be a conserved CK1 docking site in diverse classes of proteins. | DISCUSSION |
|---|
|
|
|---|
We have also shown that GSK3 does not phosphorylate the SRR-1 region but can phosphorylate the SP motifs after a priming phosphorylation. Notably, previous mass spectrometric analysis of cytoplasmic NFAT1 from resting T cells did not yield any evidence of stable, stoichiometric phosphorylation at the postulated priming sites (41) and suggested that GSK3 functions as an NFAT1 export kinase rather than as a constitutive kinase that maintains SP motif phosphorylation in resting cells. Consistent with this, the GSK3 inhibitor LiCl did not cause nuclear localization of NFAT1 even in LMB-treated cells, but it did delay NFAT1 export from the nucleus (Fig. 5). In contrast, CK1 inhibitors caused NFAT1 nuclear import in LMB-treated cells and also delayed NFAT1 export from the nucleus (Fig. 5); these results suggest that CK1 both maintains SRR-1 phosphorylation under resting conditions and plays a role in its rephosphorylation in the nucleus.
It is clear from our own previous work and that of others that the conserved SRR and SP motifs behave as individual modules that regulate NFAT function. Serine-to-alanine mutations which mimic dephosphorylation of the SRR-1 motif result in constitutive nuclear localization of NFAT proteins but do not affect the DNA binding of NFAT, indicating that the phosphorylation state of the SRR-1 motif primarily regulates exposure of the nuclear localization sequence in the regulatory domain (5, 41, 42). In contrast, the phosphorylation state of the SP motifs appears to be more important for controlling DNA binding affinity: mutations that mimic dephosphorylation of the SP motifs increase NFAT DNA binding (40) without affecting NFAT1 localization in resting cells (41). As a result, NFAT1 SRR-1 mutants are constitutively nuclear but exhibit only partial transcriptional activity under conditions where the SP motifs remain phosphorylated (J. Aramburu, H. Okamura, and A. Rao, unpublished data). Our present work demonstrating that these motifs are targeted by two different kinases sheds light on why a single protein requires so many different phosphorylation sites. Regulation of each modular cluster of phosphorylation sites by a separate kinase allows for finely tuned control over each aspect of NFAT activation, from subcellular localization to DNA binding to transcription.
Implications for differential regulation of individual NFAT family members. The level of NFAT activity at any given time is determined by the balance of calcineurin-dependent activation and kinase-mediated deactivation (23, 47, 52). Regardless of which NFAT family member is being considered, a single phosphatase, calcineurin, recognizes and dephosphorylates all phosphoserine residues relevant for NFAT activation. Yet there is growing evidence that even in a single cell, where all NFAT proteins are subject to the same parameters of Ca2+-calcineurin signaling, individual NFAT proteins may show very different patterns of subcellular localization (reviewed in reference 23). For instance, NFAT1, NFAT2, and NFAT4 are present in skeletal muscle cells at all stages of myogenesis but exhibit distinct patterns of nuclear translocation depending on the specific stage of muscle differentiation (1). Similarly, only NFAT2 translocates to the nucleus in human pulmonary valve endothelial cells treated with vascular endothelial growth factor, even though these cells also contain NFAT1 and NFAT4 (26). Likewise, NFAT2 is dephosphorylated and nuclear in T cells stimulated for 5 to 6 h, at the same time that NFAT1 is being rephosphorylated and exported to the cytoplasm (35; H. Okamura and A. Rao, unpublished data). In yet another example, NFAT3 is completely localized to the nucleus in resting astrocytes, while NFAT1 is predominantly cytoplasmic in the same cells (A. Benedito, A. Rao, and A. Bonni, unpublished data). Finally, short calcium pulses lead to sustained localization of NFAT3 in the nuclei of hippocampal neurons (19), whereas a similar short calcium pulse in T cells leads only to transient, low-level activation of NFAT1 (14, 15).
If all NFAT proteins are dephosphorylated by calcineurin, what is the basis for the differences in regulation among the NFAT family members? The concept that NFAT is regulated by multiple kinases provides a new insight into the mechanisms of NFAT activation, allowing for individual control of each family member even in the presence of an active phosphatase that is common to the regulation of all. NFAT deactivation by CK1 and GSK3 is likely to be sensitive to changes in a variety of other intracellular signaling pathways. For instance, the activity of GSK3 is suppressed by Akt, a kinase activated in response to diverse signaling pathways in different cell types (13). Additionally, GSK3 prefers targets that have been prephosphorylated by a priming kinase. Thus, after exposure to stimuli that activate calcineurin-mediated dephosphorylation, direct modification of NFAT by an inducible kinase could provide a priming phosphorylation site that would preferentially increase its sensitivity to GSK3 and facilitate rephosphorylation. The rate of NFAT deactivation would therefore be influenced by which inducible kinases were active under the particular stimulation conditions imposed and whether the NFAT proteins available to the kinases possessed the appropriate sequences for docking and target recognition.
An interesting illustration of such a mechanism is provided by mitogen-activated protein (MAP) kinases, which have been reported by several groups to oppose the nuclear accumulation of NFAT (10, 17, 42, 56). MAP kinases can selectively phosphorylate NFAT proteins at the Ser-Pro sequence at the beginning of their SRR-1 regions (see Fig. 7C); JNK1 phosphorylates NFAT2 and NFAT4 (10, 42), while p38 may selectively target NFAT1 and NFAT3 (17, 56). As inducible kinases that phosphorylate only a limited subset of residues in the NFAT regulatory domain, MAP kinases are unlikely to be responsible for maintaining NFAT proteins in a phosphorylated and inactive state in resting T cells. However, phosphorylation of the initial Ser-Pro sequence in the SRR-1 region could promote processive phosphorylation of the entire SRR-1 region by CK1. Although CK1 can clearly phosphorylate NFAT1 without any requirement for priming activity (Fig. 2D), as predicted for a constitutive kinase that maintains NFAT phosphorylation in resting cells, the MAP kinase-mediated mechanism would selectively enhance nuclear export in stimulated cells of those NFAT family members that were specific targets for the MAP kinase in question.
Parallels with other signaling pathways regulated by CK1.
In both the Wnt and Hedgehog signaling pathways, CK1 coordinates with GSK3 to phosphorylate and negatively regulate a transcription factor anchored in the cytoplasm. This echoes the theme of NFAT regulation documented in this study, although in each of these cases the kinases coordinate their activities in a slightly different way. In the case of Wnt signaling, CK1 acts as a priming kinase for GSK3 on the ß-catenin transcriptional activator (3, 34). In the Hedgehog pathway, PKA serves as a priming kinase for adjacent GSK3 and CK1 sites on the transcription factor Ci (25, 32, 43). In the Drosophila circadian clock, the PER proteins are phosphorylated by the CK1
homolog Double-time, while the heterodimeric partner of PER, Timeless, is phosphorylated by the GSK3 homolog Shaggy, which in turn may be primed by CK2 (2, 33). In contrast, for NFAT regulation, CK1 acts independently of GSK3 to phosphorylate the conserved SRR-1 motif, while the combination of a priming kinase and GSK3 could phosphorylate the conserved SP motifs to facilitate NFAT nuclear export. Notably, PKA and CK2 could conceivably both serve as priming kinases for GSK3, since they would target the same residues in the SP motifs (42, 50).
Interestingly, the F-X-X-X-F motif, which we have identified as an NFAT docking site for CK1, is also present in proteins regulated by CK1 in the Wnt and Hedgehog pathways (e.g., ß-catenin, APC), but whether the motif serves as a docking site for CK1 in these cases has not been determined. The situation is clearest for the PER proteins, which serve as both substrates and direct binding partners for CK1
, and in which the F-X-X-X-F motif is necessary for mediating CK1 association (Fig. 7B). While the presence or absence of an accessible F-X-X-X-F motif may have predictive value in determining whether or not a given protein binds directly to CK1, it is likely that other CK1 binding motifs exist, since proteins such as axin and diversin, which are thought to bind CK1, do not contain a detectable F-X-X-X-F motif.
What coordinates the activities of multiple kinases that function concurrently to control the activity of a single transcription factor sequestered in the cytoplasm? In the canonical Wnt/ß-catenin pathway, negative control of the transcriptional activator ß-catenin is exerted in the context of a cytoplasmic regulatory complex that includes the scaffolding protein axin, the tumor suppressor APC, the protein phosphatase PP2A, and the CK1 and GSK3 kinases (3, 24, 34, 48, 49, 55). In an analogous manner, it is possible that scaffolding proteins serve to assemble NFAT1 and its regulatory kinases into a multicomponent complex. The high-molecular-weight complex that contains NFAT1 and CK1 in resting T cells does not appear to contain GSK3 or calcineurin (Fig. 4), although we cannot rule out the possibility that these proteins do not remain stably associated under the conditions used. Since the apparent molecular weight of this complex is higher than that expected for NFAT1 and CK1 alone, an intriguing possibility is that adaptor proteins and additional kinase activities are present in this complex. This would be an efficient and sensitive method of finely modulating the phosphorylation status of NFAT in response to different intracellular signals, thereby regulating the subcellular localization, DNA binding, and transcriptional activity of this important transcription factor.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Present address: IBGM, Universidad de Valladolid, Valladolid, Spain. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Akten, B., E. Jauch, G. K. Genova, E. Y. Kim, I. Edery, T. Raabe, and F. R. Jackson. 2003. A role for CK2 in the Drosophila circadian oscillator. Nat. Neurosci. 6:251-257.[CrossRef][Medline]
3. Amit, S., A. Hatzubai, Y. Birman, J. S. Andersen, E. Ben-Shushan, M. Mann, Y. Ben-Neriah, and I. Alkalay. 2002. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16:1066-1076.
4. Aramburu, J., F. García-Cózar, A. Raghavan, H. Okamura, A. Rao, and P. G. Hogan. 1998. Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. Mol. Cell 1:627-637.[CrossRef][Medline]
5. Beals, C. R., N. A. Clipstone, S. N. Ho, and G. R. Crabtree. 1997. Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. Genes Dev. 11:824-834.
6. Beals, C. R., C. M. Sheridan, C. W. Turck, P. Gardner, and G. R. Crabtree. 1997. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275:1930-1933.
7. Brivanlou, A. H., and J. E. Darnell, Jr. 2002. Signal transduction and the control of gene expression. Science 295:813-818.
8. Cegielska, A., K. F. Gietzen, A. Rivers, and D. M. Virshup. 1998. Autoinhibition of casein kinase I epsilon (CKI epsilon) is relieved by protein phosphatases and limited proteolysis. J. Biol. Chem. 273:1357-1364.
9. Chijiwa, T., M. Hagiwara, and H. Hidaka. 1989. A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. J. Biol. Chem. 264:4924-4927.
10. Chow, C. W., M. Rincon, J. Cavanagh, M. Dickens, and R. J. Davis. 1997. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 278:1638-1641.
11. Crabtree, G. R. 1999. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 96:611-614.[CrossRef][Medline]
12. Crabtree, G. R., and E. N. Olson. 2002. NFAT signaling: choreographing the social lives of cells. Cell 109(Suppl.):S67-S79.
13. Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789.[CrossRef][Medline]
14. Dolmetsch, R. E., K. Xu, and R. S. Lewis. 1998. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 392:933-936.[CrossRef][Medline]
15. Feske, S., R. Draeger, H. H. Peter, K. Eichmann, and A. Rao. 2000. The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells. J. Immunol. 165:297-305.
16. Flotow, H., P. R. Graves, A. Q. Wang, C. J. Fiol, R. W. Roeske, and P. J. Roach. 1990. Phosphate groups as substrate determinants for casein kinase I action. J. Biol. Chem. 265:14264-14269.
17. Gomez del Arco, P., S. Martinez-Martinez, J. L. Maldonado, I. Ortega-Perez, and J. M. Redondo. 2000. A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp. J. Biol. Chem. 275:13872-13878.
18. Graef, I. A., F. Chen, and G. R. Crabtree. 2001. NFAT signaling in vertebrate development. Curr. Opin. Genet. Dev. 11:505-512.[CrossRef][Medline]
19. Graef, I. A., P. G. Mermelstein, K. Stankunas, J. R. Neilson, K. Deisseroth, R. W. Tsien, and G. R. Crabtree. 1999. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature 401:703-708.[CrossRef][Medline]
20. Graves, P. R., and P. J. Roach. 1995. Role of COOH-terminal phosphorylation in the regulation of casein kinase I delta. J. Biol. Chem. 270:21689-21694.
21. Gross, S. D., and R. A. Anderson. 1998. Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family. Cell. Signal. 10:699-711.[CrossRef][Medline]
22. Ho, A. M., J. Jain, A. Rao, and P. G. Hogan. 1994. Expression of the transciption factor NFATp in a neuronal cell line and in the murine nervous system. J. Biol. Chem. 269:181-186.
23. Hogan, P. G., L. Chen, J. Nardone, and A. Rao. 2003. Transcriptional regulation by calcium, calcineurin and NFAT. Genes Dev. 17:2205-2232.
24. Ikeda, S., S. Kishida, H. Yamamoto, H. Murai, S. Koyama, and A. Kikuchi. 1998. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3ß and beta-catenin and promotes GSK-3ß-dependent phosphorylation of beta-catenin. EMBO J. 17:1371-1384.[CrossRef][Medline]
25. Jia, J., K. Amanai, G. Wang, J. Tang, B. Wang, and J. Jiang. 2002. Shaggy/GSK3 antagonizes Hedgehog signaling by regulating Cubitus interruptus. Nature 416:548-552.[CrossRef][Medline]
26. Johnson, E. N., Y. M. Lee, T. L. Sander, E. Rabkin, F. J. Schoen, S. Kaushal, and J. Bischoff. 2003. NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells. J. Biol. Chem. 278:1686-1692.
27. Kalderon, D. 2002. Similarities between the Hedgehog and Wnt signaling pathways. Trends Cell Biol. 12:523-531.[CrossRef][Medline]
28. Kehlenbach, R. H., A. Dickmanns, and L. Gerace. 1998. Nucleocytoplasmic shuttling factors including Ran and CRM1 mediate nuclear export of NFAT in vitro. J. Cell Biol. 141:868-874.
29. Kiani, A., A. Rao, and J. Aramburu. 2000. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 12:359-372.[CrossRef][Medline]
30. Klein, P. S., and D. A. Melton. 1996. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 93:8455-8459.
31. Komeili, A., and E. K. O'Shea. 2001. New perspectives on nuclear transport. Annu. Rev. Genet. 35:341-364.[CrossRef][Medline]
32. Lefers, M. A., and R. Holmgren. 2002. Ci proteolysis: regulation by a constellation of phosphorylation sites. Curr. Biol. 12:R422-R423.[CrossRef][Medline]
33. Lin, J. M., V. L. Kilman, K. Keegan, B. Paddock, M. Emery-Le, M. Rosbash, and R. Allada. 2002. A role for casein kinase 2 alpha in the Drosophila circadian clock. Nature 420:816-820.[CrossRef][Medline]
34. Liu, C., Y. Li, M. Semenov, C. Han, G. H. Baeg, Y. Tan, Z. Zhang, X. Lin, and X. He. 2002. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837-847.[CrossRef][Medline]
35. Loh, C., J. A. Carew, J. Kim, P. G. Hogan, and A. Rao. 1996. T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1. Mol. Cell. Biol. 16:3945-3954.[Abstract]
36. Luo, C., E. Burgeon, J. A. Carew, P. G. McCaffrey, T. M. Badalian, W. S. Lane, P. G. Hogan, and A. Rao. 1996. Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes. Mol. Cell. Biol. 16:3955-3966.[Abstract]
37. Luo, C., K. T. Shaw, A. Raghavan, J. Aramburu, F. Garcia-Cozar, B. A. Perrino, P. G. Hogan, and A. Rao. 1996. Interaction of calcineurin with a domain of the transcription factor NFAT1 that controls nuclear import. Proc. Natl. Acad. Sci. USA 93:8907-8912.
38. Massari, M. E., P. A. Grant, M. G. Pray-Grant, S. L. Berger, J. L. Workman, and C. Murre. 1999. A conserved motif present in a class of helix-loop-helix proteins activates transcription by direct recruitment of the SAGA complex. Mol. Cell 4:63-73.[CrossRef][Medline]
39. Meggio, F., J. W. Perich, E. C. Reynolds, and L. A. Pinna. 1991. A synthetic beta-casein phosphopeptide and analogues as model substrates for casein kinase-1, a ubiquitous, phosphate directed protein kinase. FEBS Lett. 283:303-306.[CrossRef][Medline]
40. Neal, J. W., and N. A. Clipstone. 2001. Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. J. Biol. Chem. 276:3666-3673.
41. Okamura, H., J. Aramburu, C. Garcia-Rodriguez, J. P. Viola, A. Raghavan, M. Tahiliani, X. Zhang, J. Qin, P. G. Hogan, and A. Rao. 2000. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol. Cell 6:539-550.[CrossRef][Medline]
42. Porter, C. M., M. A. Havens, and N. A. Clipstone. 2000. Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization. J. Biol. Chem. 275:3543-3551.
43. Price, M. A., and D. Kalderon. 2002. Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1. Cell 108:823-835.[CrossRef][Medline]
44. Rao, A., S. J. Faas, and H. Cantor. 1984. Activation specificity of arsonate-reactive T cell clones: structural requirements for hapten recognition and comparison with monoclonal antibodies. J. Exp. Med. 159:479-485.
45. Rao, A., C. Luo, and P. G. Hogan. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:707-747.[CrossRef][Medline]
46. Rivers, A., K. F. Gietzen, E. Vielhaber, and D. M. Virshup. 1998. Regulation of casein kinase I epsilon and casein kinase I delta by an in vivo futile phosphorylation cycle. J. Biol. Chem. 273:15980-15984.
47. Salazar, C., and T. Höfer. 2003. Allosteric regulation of the transcription factor NFAT1 by multiple phosphorylation sites: a mathematical analysis. J. Mol. Biol. 327:31-45.[CrossRef][Medline]
48. Schwarz-Romond, T., C. Asbrand, J. Bakkers, M. Kuhl, H. J. Schaeffer, J. Huelsken, J. Behrens, M. Hammerschmidt, and W. Birchmeier. 2002. The ankyrin repeat protein diversin recruits casein kinase I
to the beta-catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling. Genes Dev. 16:2073-2084.
49. Seeling, J. M., J. R. Miller, R. Gil, R. T. Moon, R. White, and D. M. Virshup. 1999. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 283:2089-2091.
50. Sheridan, C. M., E. K. Heist, C. R. Beals, G. R. Crabtree, and P. Gardner. 2002. Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. J. Biol. Chem. 277:48664-48676.
51. Toh, K. L., C. R. Jones, Y. He, E. J. Eide, W. A. Hinz, D. M. Virshup, L. J. Ptacek, and Y. H. Fu. 2001. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 291:1040-1043.
52. Tomida, T., K. Hirose, A. Takizawa, F. Shibasaki, and M. Iino. 2003. NFAT functions as a working memory of Ca2+ signals in decoding Ca2+ oscillation. EMBO J. 22:3825-3832.[CrossRef][Medline]
53. Vielhaber, E., E. Eide, A. Rivers, Z. H. Gao, and D. M. Virshup. 2000. Nuclear entry of the circadian regulator mPER1 is controlled by mammalian casein kinase I epsilon. Mol. Cell. Biol. 20:4888-4899.
54. Wolff, B., J. J. Sanglier, and Y. Wang. 1997. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol. 4:139-147.[CrossRef][Medline]
55. Yanagawa, S., Y. Matsuda, J. S. Lee, H. Matsubayashi, S. Sese, T. Kadowaki, and A. Ishimoto. 2002. Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila. EMBO J. 21:1733-1742.[CrossRef][Medline]
56. Yang, T. T., Q. Xiong, H. Enslen, R. J. Davis, and C. W. Chow. 2002. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol. Cell. Biol. 22:3892-3904.
57. Zhu, J., and F. McKeon. 1999. NF-AT activation requires suppression of Crm1-dependent export by calcineurin. Nature 398:256-260.[CrossRef][Medline]
58. Zhu, J., F. Shibasaki, R. Price, J.-C. Guillemot, T. Yano, V. Dotsch, G. Wagner, P. Ferrara, and F. McKeon. 1998. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell 93:851-861.[CrossRef][Medline]
This article has been cited by other articles: